Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Pharmacokinetics of Oral Cefatrizine in Pregnant and Non-Pregnant Women with Reference to Fetal Distribution

Papantoniou N. · Ismailos G. · Daskalakis G. · Karabinas C. · Mesogitis S. · Papapanagiotou A. · Antsaklis A.

Author affiliations

First Department of Obstetrics and Gynecology, University of Athens, ‘Alexandra’ Hospital, Athens, Greece

Related Articles for ""

Fetal Diagn Ther 2007;22:100–106

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Received: August 22, 2005
Accepted: April 05, 2006
Published online: November 27, 2006
Issue release date: February 2007

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 1

ISSN: 1015-3837 (Print)
eISSN: 1421-9964 (Online)

For additional information: https://www.karger.com/FDT

Abstract

Objective: To investigate the effect of gestation on the pharmacokinetics of orally administered β-lactams, choosing cefatrizine as the model antibiotic. Setting: A tertiary teaching hospital. Design: Prospective study. Methods: In 20 women with affected fetuses, 17 by β-thalassemia major and 3 with congenital malformations, termination of gestation between 19 and 24 weeks was induced by intra-amniotic administration of prostaglandin F2α. Pharmacokinetics of cefatrizine in maternal and fetal blood were studied after the administration of three 1 g doses of oral cefatrizine, every 12 h. Twenty female non-pregnant volunteers consisted the control group. Results: Gestation was found to decrease substantially both cefatrizine oral bioavailability and maximum serum plasma concentration (42.8 and 44.5%, respectively) but increased elimination half-life. This effect can be attributed to a substantial increase of the apparent volume of distribution of cefatrizine in relation to a moderate increase of clearance that occurs during pregnancy. Fetal serum cefatrizine levels were lower for the first few hours after administration and then exceeded the corresponding maternal ones. Conclusions: Our results indicate that gestation decreases the oral bioavailability of cefatrizine. A delay in the maternal drug elimination compared to non-pregnant controls was more pronounced in the fetus.

© 2007 S. Karger AG, Basel


References

  1. Heikkila A, Erkkola R: Review of β-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules. Clin Pharmacokinet 1994;27:49–62.
  2. Aderson G: Pregnancy-induced changes in pharmacokinetics. A mechanistic-based approach. Clin Pharmacokinet 2005;44:989–1008.
  3. Pacifici GM, Nottoli R: Placental transfer of drugs administered to the mother. Clin Pharmacokinet 1995;28:235–269.
  4. Func-Tomc JC, Huczko E, Stickle T, et al: Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides. Antimicrob Agents Chemother 1995;39:533–538.
  5. Franchini F, Scaglione F, Proto M, et al: Kinetics of cefatrizine penetration into gynecological tissues after oral administration. Chemotherapy 1987;33:93–96.
  6. Kanao M, Sato S, Itoh M, Okada H: Clinical evaluation of cefatrizine in the field of obstetrics and gynecology. Jpn J Antibiot 1981;34:453–458.
  7. Uri JV: Stability of cefatrizine in aqueous solution and in sera. Acta Microbiol Hung 1986;33:177–182.
  8. Crombez E, Van Der Weken G, Van Den Bossche, et al: Determination of cefatrizine in serum and urine by reversed-phase high-performance liquid chromatography. J Chromatogr 1979;173:165–173.
  9. Pfeffer M, Gaver R, Ximenez J: Human Intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine. Antimicrob Agents Chemother 1983;24:915–920.
  10. Heikkila A, Erkkola R: The need for adjustment of dosage regimen of penicillin V during pregnancy. Obstet Gynecol 1993;81:919–921.
  11. Bourget P, Sertin A, Lesne-Hulin A, et al: Influence of pregnancy on the pharmacokinetic behaviour and the transplacental transfer of the piperacillin-tazobactam combination. Eur J Obstet Gynecol Reprod Biol 1998;76:21–27.
  12. Tsuji A, Nakashima E, Nishide K, et al: Physicochemical properties of amphoteric b-lactam antibiotics. III. Stability, solubility, and dissolution behavior of cefatrizine and cefadroxil as a function of pH. Chem Pharm Bull 1983;31:4057–4069.
  13. Reinger B, Couet W, Guedes J, Fourtillan J, Tozer T: Saturable rate of cefatrizine absorption after oral administration to humans. J Pharmacokinet Biopharm 1990;18:17–34.
  14. Rowland M, Tozer T: Clinical Pharmacokinetics. Concepts and Applications. Chapter 11, ed 3: Williams & Wilkins, 1995.
  15. Wise R, Gillet A, Cadge B, et al: The influence of protein binding upon tissue fluid levels of six beta-lactams. J Infect Dis 1980;142:77–82.
  16. Herngren L, Ehredo M, Boreus L: Drug distribution in whole blood of mothers and their newborn infants. Studies of cloxacillin and flucloxacillin. Eur J Clin Pharmacol 1982;22:351–358.
  17. Kubacha T, Johnstone E, Tan I, Reeme D, Myre A: Intravenous ampicillin pharmacokinetics in the third trimester of pregnancy. Ther Drug Monit 1983;5:55–60.
  18. Philipson A: Pharmacokinetics of ampicillin during pregnancy. J Infect Dis 1977;136:370–376.
  19. Kubacha T, Johnstone E, Tan I, Reeme D, Myre A: Intravenous ampicillin pharmacokinetics in the third trimester of pregnancy. Ther Drug Monit 1983;5:55–60.
  20. Philipson A, Stiernstede G: Pharmacokinetics of cefuroxime in pregnancy. Am J Obstet Gynecol 1982;142:823–828.
  21. Heikkila A, Erkkola R: Pharmacokinetics of piperacillin during pregnancy. J Antimicrob Chemother 1991;28:419–423.
  22. Voigt R, Schroder S, Peiker G: Pharmacokinetic studies of azlocillin and piperacillin during late pregnancy. Chemother 1985;31:417–424.
  23. Giamarellou H, Gazis J, Petrikkos G, et al: A study of cefoxitin, moxalactam, and ceftazidime kinetics in pregnancy. Am J Obstet Gynecol 1983;147:914–919.
  24. Heikkila A, Renkonen V, Erkkola R: Pharmacokinetics and placental passage of imipenem during pregnancy. Antimicrob Agents Chemother 1992;36:2652–2655.
  25. Bernard B, Barton L, Abate M, et al: Maternal-fetal transfer of cefazolin in the first twenty weeks of pregnancy. J Infect Dis 1977;136:377–382.
  26. Krauer B, Dayer P, Anner R: Changes in serum albumin and α1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs. Br J Obstet Gynecol 1984;91:875–881.
  27. Fernandez H, Bourget P, Delouis C, Demirjian S: Administration de la tobramycin au cours du deuxieme et du troisieme trimestre de la grossesse: Apport d’une etude pharmacocinetique pour l’adaptation de la posodologie. J Gynecol Biol Reprod 1991;20:107–115.
  28. Ward R: Drug therapy of the fetus. J Clin Pharmacol 1993;33:780–789.
  29. Nau H: Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. Dev Pharmacol Ther 1987;10:174–198.
  30. Drusano GL: Role of pharmakocinetics in the outcome of infections. Antimicrob Agents Chemother 1988;32:289–297.

Article / Publication Details

First-Page Preview
Abstract of Paper

Received: August 22, 2005
Accepted: April 05, 2006
Published online: November 27, 2006
Issue release date: February 2007

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 1

ISSN: 1015-3837 (Print)
eISSN: 1421-9964 (Online)

For additional information: https://www.karger.com/FDT


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.